Gerson Hernandez
- Senior Director, Clinical Trials - Center for Innovation in Brain Science
- Assistant Research Professor, Neurology
Contact
- (520) 626-5781
- Bioscience Research Labs, Rm. 472
- Tucson, AZ 85721
- gersonhe@arizona.edu
Degrees
- MPH Medicine
- University of Southern California, Los Angeles, California, United States
- M.D. Medicine
- Universidad Francisco Marroquin, Guatemala City, Guatemala
- Gestational diabetes in indigenous women from San Juan Sacatepequez, Guatemala. Thesis, Francisco Marroquin University. 1-47, 2003.
Awards
- AZ ADRC-REC Fellowship
- Arizona Alzheimer’s Disease Research Center, Spring 2021
Interests
Research
Alzheimer's disease and other neurodegenerative diseases / Brain health / Women's health
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Brinton, R. D., Hernandez, G. D., Raikes, A. C., Matthews, D. C., Lukic, A. S., Law, M., Shi, Y., & Schneider, L. S. (2022). Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 8(1). doi:10.1002/trc2.12258
- Chilton, F., Killgore, W. D., Mullins, V. A., Hernandez, G. D., Raikes, A. C., Wang, Y., Lopez, C. M., & Brinton, R. D. (2022). In‐season docosahexaenoic acid supplementation does not prevent white matter damage during a single American football season: Implications for neurodegeneration prevention. Alzheimer's & Dementia, 18(S11). doi:10.1002/alz.065751
- Hernandez, G. D., Brinton, R. D., Schneider, L. S., Cutter, G. R., Matthews, D. C., Rodgers, K. E., Raikes, A. C., & Lopez, C. M. (2022). Allopregnanolone as a Regenerative Therapeutic for Alzheimer’s Disease: Phase 2 proof‐of‐concept clinical trial using hippocampal volume as a surrogate endpoint. Alzheimers & Dementia, 18(S10). doi:10.1002/alz.068251
- Brinton, R. D., Rodgers, K. E., Hernandez, G. D., Solinsky, C. M., Mack, W. J., Kono, N., Wu, C., Mollo, A. R., Lopez, C. M., Pawluczyk, S., Bauer, G., Matthews, D., Shi, Y., Law, M., Rogawski, M. A., & Schneider, L. S. (2020). Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 6(1). doi:10.1002/trc2.12107
- Hernandez, G. D., Solinsky, C. M., Mack, W. J., Kono, N., Rodgers, K. E., Wu, C. Y., Mollo, A. R., Lopez, C. M., Pawluczyk, S., Bauer, G., Matthews, D., Shi, Y., Law, M., Rogawski, M. A., Schneider, L. S., & Brinton, R. D. (2020). Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimer's & dementia (New York, N. Y.), 6(1), e12107.More infoAllopregnanolone is an endogenous neurosteroid with the potential to be a novel regenerative therapeutic for Alzheimer's disease (AD). Foundations of mechanistic understanding and well-established preclinical safety efficacy make it a viable candidate.
- Rodgers, K. E., Hernandez, G. D., Lopez, C. M., Wang, Y., Schneider, L., & Brinton, R. D. (2020). Pharmacokinetics and safety profile of intramuscular administration of allopregnanolone in patients with Alzheimer’s disease: Human/Human trials: Other. Alzheimer's & Dementia, 16(S9). doi:10.1002/alz.046223
- Brinton, R. D., Hernandez, G. D., Wang, Y., Solinsky, C. M., & Schneider, L. S. (2019). P3-032: COMBINING SEX, APOE GENOTYPE, AND MITOCHONDRIAL GENETIC VARIANCE AS PREDICTIVE RESPONDER IDENTIFIER TO REGENERATIVE THERAPEUTIC ALLOPREGNANOLONE FOR ALZHEIMER'S DISEASE. Alzheimer's & Dementia, 15(7S_Part_4), P938-P938. doi:10.1016/j.jalz.2019.06.3058
